{"organizations": [], "uuid": "e5bfd5977a2398a5648f86d09446810b030ed8e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-wave-life-sciences-and-takeda-form/brief-wave-life-sciences-and-takeda-form-strategic-collaboration-to-advance-therapies-for-central-nervous-system-disorders-idUSFWN1QA0JW", "country": "US", "domain_rank": 408, "title": "BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.095, "site_type": "news", "published": "2018-02-20T20:28:00.000+02:00", "replies_count": 0, "uuid": "e5bfd5977a2398a5648f86d09446810b030ed8e1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-wave-life-sciences-and-takeda-form/brief-wave-life-sciences-and-takeda-form-strategic-collaboration-to-advance-therapies-for-central-nervous-system-disorders-idUSFWN1QA0JW", "ord_in_thread": 0, "title": "BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders", "locations": [], "entities": {"persons": [], "locations": [{"name": "huntington", "sentiment": "none"}], "organizations": [{"name": "takeda pharmaceutical co ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "takeda", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Takeda Pharmaceutical Co Ltd:\n* WAVE LIFE SCIENCES AND TAKEDA FORM GLOBAL STRATEGIC COLLABORATION TO ADVANCE THERAPIES FOR CENTRAL NERVOUS SYSTEM DISORDERS\n* WAVE LIFE SCIENCES LTD - UNDER COLLABORATION, CO TO PROVIDE TAKEDA OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE PROGRAMS IN HUNTINGTON‘S DISEASE\n* WAVE LIFE SCIENCES - CO WILL ALSO PROVIDE TAKEDA OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE PROGRAMS IN AMYOTROPHIC LATERAL SCLEROSIS, AMONG OTHERS\n* WAVE LIFE SCIENCES LTD - UNDER TERMS OF TWO-COMPONENT AGREEMENT, TAKEDA WILL MAKE AN INITIAL PAYMENT OF $110 MILLION TO WAVE\n* WAVE LIFE SCIENCES LTD - UNDER TERMS OF TWO-COMPONENT AGREEMENT, TAKEDA WILL PURCHASE $60 MILLION OF WAVE‘S ORDINARY SHARES AT $54.70 PER SHARE\n* WAVE LIFE SCIENCES LTD - TAKEDA WILL ALSO FUND AT LEAST $60 MILLION OF WAVE RESEARCH OVER A FOUR-YEAR PERIOD\n* WAVE LIFE SCIENCES - TAKEDA TO HAVE RIGHT TO LICENSE MULTIPLE PRECLINICAL PROGRAMS TARGETING CNS DISORDERS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T20:28:00.000+02:00", "crawled": "2018-02-21T21:17:17.011+02:00", "highlightTitle": ""}